{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:15:11Z","timestamp":1789748111096,"version":"4.0.1"},"reference-count":153,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Microbiol Rev"],"published-print":{"date-parts":[[2020,9,16]]},"abstract":"<jats:p>Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging infectious diseases; its efficacy was later associated with the evidence that polyclonal neutralizing antibodies can reduce the duration of viremia. Recent large outbreaks of viral diseases for which effective antivirals or vaccines are still lacking has renewed the interest in CP as a life-saving treatment. The ongoing COVID-19 pandemic has led to the scaling up of CP therapy to unprecedented levels. Compared with historical usage, pathogen reduction technologies have now added an extra layer of safety to the use of CP, and new manufacturing approaches are being explored.<\/jats:p>","DOI":"10.1128\/cmr.00072-20","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T14:12:41Z","timestamp":1597155161000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":99,"title":["Convalescent Plasma Therapy for COVID-19: State of the Art"],"prefix":"10.1128","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-195X","authenticated-orcid":false,"given":"Daniele","family":"Focosi","sequence":"first","affiliation":[{"name":"North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur O.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Respiratory Mucosal Immunity, US Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian W.","family":"Tang","sequence":"additional","affiliation":[{"name":"Respiratory Sciences, University of Leicester, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tuccori","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"},{"name":"Unit of Adverse Drug Reaction Monitoring, Pisa University Hospital, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00028-20"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00072-15"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.08.006"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00135"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0233-2"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00318-1"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03020-3"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu396"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102847"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa449"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1271-9"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12940"},{"key":"e_1_3_1_14_2","doi-asserted-by":"crossref","unstructured":"Harvala H Robb M Watkins N Ijaz S Dicks S Patel M Supasa P Dejnirattisai W Liu C Mongkolsapaya J Brown A Bailey D Vipond R Grayson N Temperton N Bolton J Fyfe A Gopal R Simmonds P Screaton G Thompson CP Brooks T Zambon M Miflin G Roberts D. 26 May 2020. Convalescent plasma therapy for the treatment of patients with COVID-19: assessment of methods available for antibody detection and their correlation with neutralising antibody levels. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.05.20.20091694v1.","DOI":"10.1101\/2020.05.20.20091694"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","unstructured":"Phelan J Deelder W Ward D Campino S Hibberd ML Clark TG. 2020. Controlling the SARS-CoV-2 outbreak insights from large scale whole genome sequences generated across the world. bioRxiv https:\/\/www.biorxiv.org\/content\/10.1101\/2020.04.28.066977v1.","DOI":"10.1101\/2020.04.28.066977"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9050324"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","unstructured":"Zhang L Jackson CB Mou H Ojha A Rangarajan ES Izard T Farzan M Choe H. 2020. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv https:\/\/www.biorxiv.org\/content\/10.1101\/2020.06.12.148726v1.","DOI":"10.1101\/2020.06.12.148726"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2209.151164"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","unstructured":"Salazar E Kuchipudi SV Christensen PA Eagar TN Yi X Zhao P Jin Z Long SW Olsen RJ Chen J Castillo B Leveque C Towers DM Lavinder J Gollihar JD Cardona J Ippolito GC Nissly RH Bird IM Greenawalt D Rossi RM Gontu A Srinivasan S Poojary IB Cattadori IM Hudson PJ Joselyn N Prugar L Huie K Herbert A Bernard DW Dye J Kapur V Musser JM. 2020. Relationship between anti-Spike protein antibody titers and SARS-CoV-2 in vitro virus neutralization in convalescent plasma. bioRxiv https:\/\/www.biorxiv.org\/content\/10.1101\/2020.06.08.138990v1.","DOI":"10.1101\/2020.06.08.138990"},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","unstructured":"Klein S Pekosz A Park H-S Ursin R Shapiro J Benner S Littlefield K Kumar S Naik HM Betenbaugh M Shrestha R Wu A Hughes R Burgess I Caturegli P Laeyendecker O Quinn T Sullivan D Shoham S Redd A Bloch E Casadevall A Tobian A. 2020. Sex age and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.06.26.20139063v1.","DOI":"10.1101\/2020.06.26.20139063"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","unstructured":"Madariaga MLL Guthmiller J Schrantz S Jansen M Christenson C Kumar M Prochaska M Wool G Durkin A Oh WH Trockman L Vigneswaran J Keskey R Shaw DG Dugan H Zheng N Cobb M Utset H Wang J Stovicek O Bethel C Matushek S Giurcanu M Beavis K diSabato D Meltzer D Ferguson M Kress JP Shanmugarajah K Matthews J Fung J Wilson P Alverdy JC Donington J. 2020. Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.06.21.20132944v1.","DOI":"10.1101\/2020.06.21.20132944"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","unstructured":"Robbiani DF Gaebler C Muecksch F Cetrulo Lorenzi J Wang Z Cho A Agudelo M Barnes C Finkin S Hagglof T Oliveira T Viant C Hurley A Millard K Kost R Cipolla M Gazumyan A Gordon K Bianchini F Chen S Ramos V Patel R Dizon J Shimeliovich I Mendoza P Hartweger H Nogueira L Pack M Horowitz J Schmidt F Weisblum Y Hoffmann H-H Michailidis E Ashbrook A Waltari EF Pak J Huey-Tubman K Koranda N Hoffman P West A Rice C Hatziioannou T Bjorkman P Bieniasz P Caskey M Nussenzweig M. 2020. Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. bioRxiv https:\/\/www.biorxiv.org\/content\/10.1101\/2020.05.13.092619v1.","DOI":"10.1101\/2020.05.13.092619"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15842"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102792"},{"key":"e_1_3_1_25_2","unstructured":"FDA. 2020. Recommendations for investigational COVID-19 convalescent plasma. https:\/\/www.fda.gov\/vaccines-blood-biologics\/investigational-new-drug-ind-or-device-exemption-ide-process-cber\/recommendations-investigational-covid-19-convalescent-plasma."},{"key":"e_1_3_1_26_2","volume-title":"An EU programme of COVID-19 convalescent plasma collection and transfusion: guidance on collection, testing, processing, storage, distribution and monitored use","author":"European Commission","year":"2020","unstructured":"European Commission. 2020. An EU programme of COVID-19 convalescent plasma collection and transfusion: guidance on collection, testing, processing, storage, distribution and monitored use. European Commission, Brussels, Belgium."},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2009.00963.x"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2003.00265.x"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02651.x"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00867.x"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01238.x"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1006\/biol.2002.0334"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1006\/biol.2002.0332"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00435.x"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/94.11.599"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165.2.364"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.4.1195"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01226.x"},{"key":"e_1_3_1_39_2","first-page":"189","article-title":"Annex 4. Recommendations for the collection, quality control and regulation of human plasma for fractionation","volume":"941","author":"WHO","year":"2007","unstructured":"WHO. 2007. Annex 4. Recommendations for the collection, quality control and regulation of human plasma for fractionation. World Health Organ Tech Rep Ser 941:189\u2013264.","journal-title":"World Health Organ Tech Rep Ser"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-2824.2009.01218.x"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003501"},{"key":"e_1_3_1_42_2","volume-title":"Guide to the preparation, use and quality assurance of blood components","author":"European Directorate for the Quality of Medicines and Health Care","year":"2017","unstructured":"European Directorate for the Quality of Medicines and Health Care. 2017. Guide to the preparation, use and quality assurance of blood components, 19th ed. European Directorate for the Quality of Medicines and Health Care, Strasbourg, France.","edition":"19"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.10.1.19-21.2003"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e239"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1086\/500469"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1310.070576"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00179.x"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki346"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00956.x"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0958-7578.2005.00588.x"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12888"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00976.x"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2004.00577.x"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2005.01.003"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2307.170310"},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3243"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2016.36.4.393"},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1490-9"},{"key":"e_1_3_1_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14652"},{"key":"e_1_3_1_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14422"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13860"},{"key":"e_1_3_1_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12261"},{"key":"e_1_3_1_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017"},{"key":"e_1_3_1_65_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138003"},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30141-9"},{"key":"e_1_3_1_67_2","doi-asserted-by":"crossref","unstructured":"Sterlin D Mathian A Miyara M Mohr A Anna F Claer L Quentric P Fadlallah J Ghillani P Gunn C Hockett R Mudumba S Guihot A Luyt C-E Mayaux J Beurton A Fourati S Lacorte J-M Yssel H Parizot C Dorgham K Charneau P Amoura Z Gorochov G. 2020. IgA dominates the early neutralizing antibody response to SARS-CoV-2. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.06.10.20126532v1.","DOI":"10.1101\/2020.06.10.20126532"},{"key":"e_1_3_1_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa310"},{"key":"e_1_3_1_69_2","doi-asserted-by":"crossref","unstructured":"Long Q-x Deng H-j Chen J Hu J Liu B-z Liao P Lin Y Yu L-h Mo Z Xu Y-y Gong F Wu G-c Zhang X-x Chen Y-k Li Z-j Wang K Zhang X-L Tian W-g Niu C-c Yang Q-j Xiang J-l Du H-x Liu H-w Lang C Luo X-h Wu S-b Cui X-p Zhou Z Wang J Xue C-j Li X-f Wang L Tang X-j Zhang Y Qiu J-f Liu X-m Li J-j Zhang D-c Zhang F Cai X-f Wang D Hu Y Ren J-h Tang N Liu P Li Q Huang A-l. 2020. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.18.20038018v1.","DOI":"10.1101\/2020.03.18.20038018"},{"key":"e_1_3_1_70_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0897-1"},{"key":"e_1_3_1_71_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa344"},{"key":"e_1_3_1_72_2","unstructured":"Advisory Committee on the Safety of Blood Tissues and Organs. 2018. Guidelines from the expert advisory committee on the Safety of Blood Tissues and Organs (SaBTO) on measures to protect patients from acquiring hepatitis E virus via transfusion or transplantation. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/680297\/Hepatitis_E_Guidelines.pdf."},{"key":"e_1_3_1_73_2","doi-asserted-by":"crossref","unstructured":"Suthar MS Zimmerman M Kauffman R Mantus G Linderman S Vanderheiden A Nyhoff L Davis C Adekunle S Affer M Sherman M Reynolds S Verkerke H Alter DN Guarner J Bryksin J Horwath M Arthur C Saakadze N Smith GH Edupuganti S Scherer EM Hellmeister K Cheng A Morales JA Neish AS Stowell SR Frank F Ortlund E Anderson E Menachery V Rouphael N Metha A Stephens DS Ahmed R Roback J Wrammert J. 2020. Rapid generation of neutralizing antibody responses in COVID-19 patients. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.05.03.20084442v1.","DOI":"10.1101\/2020.05.03.20084442"},{"key":"e_1_3_1_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0913-5"},{"key":"e_1_3_1_75_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.12.11.1317-1321.2005"},{"key":"e_1_3_1_76_2","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12937"},{"key":"e_1_3_1_77_2","doi-asserted-by":"crossref","unstructured":"Andersson M Arancibia - Carcamo CV Auckland K Baillie JK Barnes E Beneke T Bibi S Carroll M Crook D Dingle K Dold C Downs LO Dunn L Eyre DW Gilbert Jaramillo J Harvala Simmonds H Hoosdally S Ijaz S James T James W Jeffery K Justice A Klenerman P Knight JC Knight M Liu X Lumley SF Matthews PC McNaughton AL Mentzer AJ Mongkolsapaya J Oakley S Oliveira MS Peto T Ploeg RJ Ratcliff J Roberts DJ Rudkin J Screaton G Semple MG Skelley DT Simmonds P Stoesser N Turtle L Wareing S Zambon M. 2020. SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.05.21.20105486v2.","DOI":"10.1101\/2020.05.21.20105486"},{"key":"e_1_3_1_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(20)30037-9"},{"key":"e_1_3_1_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-7963(05)80026-4"},{"key":"e_1_3_1_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15843"},{"key":"e_1_3_1_81_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783"},{"key":"e_1_3_1_82_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004168117"},{"key":"e_1_3_1_83_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25882"},{"key":"e_1_3_1_84_2","doi-asserted-by":"crossref","unstructured":"Pei S Yuan X Zhimin Zhang Z Run Yao R Xie Y Minxue Shen M Bijuan Li B Chen X Yin M. 2020. Convalescent plasma to Treat COVID-19: Chinese strategy and experiences. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.04.07.20056440v1.","DOI":"10.1101\/2020.04.07.20056440"},{"key":"e_1_3_1_85_2","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103102"},{"key":"e_1_3_1_86_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa228"},{"key":"e_1_3_1_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102820"},{"key":"e_1_3_1_88_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e149"},{"key":"e_1_3_1_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2020.06.018"},{"key":"e_1_3_1_90_2","doi-asserted-by":"publisher","DOI":"10.24875\/RIC.20000237"},{"key":"e_1_3_1_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102867"},{"key":"e_1_3_1_92_2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14025"},{"key":"e_1_3_1_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102866"},{"key":"e_1_3_1_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.06.046"},{"key":"e_1_3_1_95_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16981"},{"key":"e_1_3_1_96_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006964"},{"key":"e_1_3_1_97_2","doi-asserted-by":"crossref","unstructured":"Hartman W Hess AS Connor JP. 2020. Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the midwest. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.06.19.20135830v1.","DOI":"10.21203\/rs.3.rs-54167\/v2"},{"key":"e_1_3_1_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102821"},{"key":"e_1_3_1_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crwh.2020.e00221"},{"key":"e_1_3_1_100_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0972-8"},{"key":"e_1_3_1_101_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-020-02384-2"},{"key":"e_1_3_1_102_2","doi-asserted-by":"crossref","unstructured":"Perotti C Baldanti F Bruno R Delfante C Seminari E Casari S Percivalle E Glingani C Musella V Belliato M Garuti M Meloni F Frigato M Di Sabatino A Klersy C De Donno G Franchini M. 2020. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.05.26.20113373v1.","DOI":"10.1101\/2020.05.26.20113373"},{"key":"e_1_3_1_103_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007079"},{"key":"e_1_3_1_104_2","doi-asserted-by":"crossref","unstructured":"Liu STH Lin H-M Baine I Wajnberg A Gumprecht JP Rahman F Rodriguez D Tandon P Bassily-Marcus A Bander J Sanky C Dupper A Zheng A Altman DR Chen BK Krammer F Mendu DR Firpo-Betancourt A Levin MA Bagiella E Casadevall A Cordon-Cardo C Jhang JS Arinsburg SA Reich DL Aberg JA Bouvier NM. 2020. Convalescent plasma treatment of severe COVID-19: a matched control study. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.05.20.20102236v1.","DOI":"10.1101\/2020.05.20.20102236"},{"key":"e_1_3_1_105_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10044"},{"key":"e_1_3_1_106_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci140200"},{"key":"e_1_3_1_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.06.028"},{"key":"e_1_3_1_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.05.014"},{"key":"e_1_3_1_109_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2006691117"},{"key":"e_1_3_1_110_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X20933473"},{"key":"e_1_3_1_111_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16890"},{"key":"e_1_3_1_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105974"},{"key":"e_1_3_1_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108408"},{"key":"e_1_3_1_114_2","unstructured":"Takeda Pharmaceutical Company Ltd. 2020. Rajeev Venkayya President Global Vaccine Business Unit on the latest on the coronavirus and Takeda. https:\/\/www.takeda.com\/newsroom\/featured-topics\/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda\/."},{"key":"e_1_3_1_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.10.014"},{"key":"e_1_3_1_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61034-5"},{"key":"e_1_3_1_117_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268817001388"},{"key":"e_1_3_1_118_2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13976"},{"key":"e_1_3_1_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2004.09.004"},{"key":"e_1_3_1_120_2","doi-asserted-by":"publisher","DOI":"10.1086\/520581"},{"key":"e_1_3_1_121_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.13.7539-7544.2003"},{"key":"e_1_3_1_122_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2005.00476.x"},{"key":"e_1_3_1_123_2","doi-asserted-by":"crossref","unstructured":"Zhang B Zhou X Zhu C Feng F Qiu Y Feng J Jia Q Song Q Zhu B Wang J. 2020. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.12.20035048v1.","DOI":"10.1101\/2020.03.12.20035048"},{"key":"e_1_3_1_124_2","doi-asserted-by":"crossref","unstructured":"Tan W Lu Y Zhang J Wang J Dan Y Tan Z He X Qian C Sun Q Hu Q Liu H Ye S Xiang X Zhou Y Zhang W Guo Y Wang X-H He W Wan X Sun F Wei Q Chen C Pan G Xia J Mao Q Chen Y Deng G. 2020. Viral kinetics and antibody responses in patients with COVID-19. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.24.20042382v1.","DOI":"10.1101\/2020.03.24.20042382"},{"key":"e_1_3_1_125_2","doi-asserted-by":"crossref","unstructured":"Jiang H-W Li Y Zhang H-N Wang W Men D Yang X Qi H Zhou J Tao S-C. 2020. Global profiling of SARS-CoV-2 specific IgG\/IgM responses of convalescents using a proteome microarray. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.20.20039495v1.","DOI":"10.1101\/2020.03.20.20039495"},{"key":"e_1_3_1_126_2","doi-asserted-by":"crossref","unstructured":"Wang X Guo X Xin Q Pan Y Li J Chu Y Feng Y Wang Q. 2020. Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.04.15.20065623v3.","DOI":"10.1101\/2020.04.15.20065623"},{"key":"e_1_3_1_127_2","doi-asserted-by":"crossref","unstructured":"Wu F Wang A Liu M Wang Q Chen J Xia S Ling Y Zhang Y Xun J Lu L Jiang S Lu H Wen Y Huang J. 2020. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.30.20047365v2.","DOI":"10.1101\/2020.03.30.20047365"},{"key":"e_1_3_1_128_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-433"},{"key":"e_1_3_1_129_2","doi-asserted-by":"crossref","unstructured":"Ng K Faulkner N Cornish G Rosa A Earl C Wrobel A Benton D Roustan C Bolland W Thompson R Agua-Doce A Hobson P Heaney J Rickman H Paraskevopoulou S Houlihan CF Thomson K Sanchez E Shin GY Spyer MJ Walker PA Kjaer S Riddell A Beale R Swanton C Gandhi S Stockinger B Gamblin S McCoy LE Cherepanov P Nastouli E Kassiotis G. 2020. Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans. bioRxiv https:\/\/www.biorxiv.org\/content\/10.1101\/2020.05.14.095414v1.","DOI":"10.1101\/2020.05.14.095414"},{"key":"e_1_3_1_130_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2014.07.090"},{"key":"e_1_3_1_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2005.07.005"},{"key":"e_1_3_1_132_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0321-6"},{"key":"e_1_3_1_133_2","unstructured":"Chakraborty S Edwards K Buzzanco AS Memoli MJ Sherwood R Mallajosyula V Xie MM Gonzalez J Buffone C Kathale N Providenza S Jagannathan P Andrews JR Blish CA Krammer F Dugan H Wilson PC Pham TD Boyd SD Zhang S Taubenberger JK Morales T Schapiro JM Parsonnet J Wang TT. 2020. Symptomatic SARS-CoV-2 infections display specific IgG Fc structures. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.05.15.20103341v1."},{"key":"e_1_3_1_134_2","doi-asserted-by":"crossref","unstructured":"Larsen MD de Graaf EL Sonneveld ME Plomp HR Linty F Visser R Brinkhaus M Sustic T deTaeye SW Bentlage AEH Nouta J Natunen S Koeleman CAM Sainio S Kootstra NA Brouwer PJM Sanders RW van Gils MJ de Bruin S Vlaar APJ Zaaijer HL Wuhrer M van der Schoot CE Vidarsson G. 2020. Afucosylated immunoglobulin G responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19. bioRxiv https:\/\/www.biorxiv.org\/content\/10.1101\/2020.05.18.099507v1.","DOI":"10.1101\/2020.05.18.099507"},{"key":"e_1_3_1_135_2","doi-asserted-by":"publisher","DOI":"10.7326\/m20-2003"},{"key":"e_1_3_1_136_2","doi-asserted-by":"crossref","unstructured":"D\u00edez J-M Romero C Gajardo R. 2020. Currently available intravenous immunoglobulin (Gamunex \u00a9 -C and Flebogamma \u00a9 DIF) contains antibodies reacting against SARS-CoV-2 antigens. bioRxiv https:\/\/www.biorxiv.org\/content\/10.1101\/2020.04.07.029017v1.","DOI":"10.1101\/2020.04.07.029017"},{"key":"e_1_3_1_137_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa102"},{"key":"e_1_3_1_138_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.12.1450-c"},{"key":"e_1_3_1_139_2","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwn093"},{"key":"e_1_3_1_140_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4267"},{"key":"e_1_3_1_141_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008556"},{"key":"e_1_3_1_142_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00315-07"},{"key":"e_1_3_1_143_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13337-020-00571-5"},{"key":"e_1_3_1_144_2","doi-asserted-by":"crossref","unstructured":"Zhao J Yang Y Huang H Li D Gu D Lu X Zhang Z Liu L Liu T Liu Y He Y Sun B Wei M Yang G Wang X Zhang L Zhou X Xing M Wang PG. 2020. Relationship between the ABO blood group and the COVID-19 susceptibility. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.11.20031096v2.","DOI":"10.1101\/2020.03.11.20031096"},{"key":"e_1_3_1_145_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16797"},{"key":"e_1_3_1_146_2","doi-asserted-by":"crossref","unstructured":"Zeng X Fan H Lu D Huang F Meng X Li Z Tang M Zhang J Liu N Liu Z Zhao J Yin W An Q Zhang X Hu X. 2020. Association between ABO blood groups and clinical outcome of coronavirus disease 2019: evidence from two cohorts. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.04.15.20063107v1%20.","DOI":"10.1101\/2020.04.15.20063107"},{"key":"e_1_3_1_147_2","doi-asserted-by":"crossref","unstructured":"Zietz M Tatonetti NP. 2020. Testing the association between blood type and COVID-19 infection intubation and death. medRxiv https:\/\/www.medrxiv.org\/content\/10.1101\/2020.04.08.20058073v1.","DOI":"10.1101\/2020.04.08.20058073"},{"key":"e_1_3_1_148_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2020283"},{"key":"e_1_3_1_149_2","doi-asserted-by":"publisher","DOI":"10.4103\/0973-6247.200765"},{"key":"e_1_3_1_150_2","doi-asserted-by":"publisher","DOI":"10.5581\/1516-8484.20110073"},{"key":"e_1_3_1_151_2","doi-asserted-by":"publisher","DOI":"10.1177\/2047487320922370"},{"key":"e_1_3_1_152_2","doi-asserted-by":"publisher","DOI":"10.1177\/2047487320931305"},{"key":"e_1_3_1_153_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16932"},{"key":"e_1_3_1_154_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2014.10.003"}],"container-title":["Clinical Microbiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.00072-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.00072-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T12:59:19Z","timestamp":1645621159000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CMR.00072-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":153,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,9,16]]}},"alternative-id":["10.1128\/CMR.00072-20"],"URL":"https:\/\/doi.org\/10.1128\/cmr.00072-20","relation":{},"ISSN":["0893-8512","1098-6618"],"issn-type":[{"value":"0893-8512","type":"print"},{"value":"1098-6618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"assertion":[{"value":"2020-08-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00072-20"}}